MediWound COO reports initial share and option stake

MediWound Ltd. executive Hess Shmuel, the company’s COO and Chief Commercial Officer, reported his existing equity stake in a Form 3 insider filing.

Rhea-AI Filing Summary

MediWound Ltd. executive Hess Shmuel, the company’s COO and Chief Commercial Officer, reported his existing equity stake in a Form 3 insider filing. The filing lists stock options to acquire 32,000, 32,681, 24,000 and 31,000 ordinary shares at exercise prices of $8.1292, $12.7290, $18.5400 and $17.6000, expiring between December 1, 2033 and March 4, 2036.

He also reports direct holdings of 4,085, 3,000 and 3,800 ordinary shares, which footnotes explain are tied to restricted share units granted in 2024, 2025 and 2026, each vesting over four years. The Form 3 establishes his current ownership position and does not show any recent share purchases or sales.

Insider Trade Summary

7 transactions reported

Mixed 7 txns

Insider Hess Shmuel

Role COO & Chief Commercial Officer

Type	Security	Shares	Price	Value
holding	Stock Option (right to buy ordinary shares)	--	--	--
holding	Stock Option (right to buy ordinary shares)	--	--	--
holding	Stock Option (right to buy ordinary shares)	--	--	--
holding	Stock Option (right to buy ordinary shares)	--	--	--
holding	Ordinary shares	--	--	--
holding	Ordinary shares	--	--	--
holding	Ordinary shares	--	--	--

Holdings After Transaction: Stock Option (right to buy ordinary shares) — 119,681 contracts (Direct); Ordinary shares — 10,885 shares (Direct)

Footnotes (7)

1. F1. The ordinary shares reported in this row consist of shares underlying restricted share units ("RSUs") that were granted to the Reporting Person on February 26, 2024 and vest in accordance with the following schedule: 25% of the RSUs vested upon the one-year anniversary of the grant date, and an additional 6.25% of the RSUs vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.
2. F2. The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on February 11, 2025 and vest in accordance with the following schedule: 25% of the RSUs vested upon the one-year anniversary of the grant date, and an additional 6.25% of the RSUs vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.
3. F3. The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on March 4, 2026 and vest in accordance with the following schedule: 25% of the RSUs vested upon the one-year anniversary of the grant date, and an additional 6.25% of the RSUs vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.
4. F4. The options reported in this row are the remaining outstanding options from a grant of 39,000 options that were granted to the Reporting Person on December 1, 2023 and that have been vesting in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.
5. F5. The options reported in this row were granted to the Reporting Person on February 26, 2024 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.
6. F6. The options reported in this row were granted to the Reporting Person on February 11, 2025 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.
7. F7. The options reported in this row were granted to the Reporting Person on March 4, 2026 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does MediWound (MDWD) COO Hess Shmuel report in this Form 3?

He reports his existing equity stake, including stock options and ordinary shares in MediWound. The filing lists several option grants and direct share holdings, outlining his current ownership position as an executive officer without showing new market transactions.

How many MediWound stock options does Hess Shmuel report holding?

He reports stock options linked to 32,000, 32,681, 24,000 and 31,000 underlying ordinary shares. These options have exercise prices between $8.1292 and $18.5400 and expire from December 2033 through March 2036, reflecting multiple long-term incentive grants.

What ordinary share holdings does Hess Shmuel disclose in MediWound (MDWD)?

He discloses direct holdings of 4,085, 3,000 and 3,800 ordinary shares. Footnotes state these positions consist of shares underlying restricted share units granted in 2024, 2025 and 2026, which vest gradually over a four-year schedule.

Are there any MediWound share purchases or sales in this Form 3 filing?

No share purchases or sales are reported; the filing only lists existing holdings. Transaction summary data show zero buy or sell entries, indicating this Form 3 serves to record Hess Shmuel’s current ownership when he became a reportable insider.

How do the MediWound RSU grants to Hess Shmuel vest over time?

Each RSU grant vests 25% on the one-year anniversary of the grant date, with an additional 6.25% vesting quarterly over the next three years. This four-year schedule applies to RSUs granted in 2024, 2025 and 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/18/2026 - 05:22 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Hess Shmuel

(Last) (First) (Middle)

C/O MEDIWOUND LTD.

42 HAYARKON STREET

(Street)

YAVNE 8122745

(City) (State) (Zip)

ISRAEL

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
MediWound Ltd. [ MDWD ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	COO & Chief Commercial Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary shares(1)	4,085	D
Ordinary shares(2)	3,000	D
Ordinary shares(3)	3,800	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy ordinary shares)	(4)	12/01/2033	Ordinary shares	32,000	$8.1292	D
Stock Option (right to buy ordinary shares)	(5)	02/26/2034	Ordinary shares	32,681	$12.729	D
Stock Option (right to buy ordinary shares)	(6)	02/11/2035	Ordinary shares	24,000	$18.54	D
Stock Option (right to buy ordinary shares)	(7)	03/04/2036	Ordinary shares	31,000	$17.6	D

Explanation of Responses:

1. The ordinary shares reported in this row consist of shares underlying restricted share units ("RSUs") that were granted to the Reporting Person on February 26, 2024 and vest in accordance with the following schedule: 25% of the RSUs vested upon the one-year anniversary of the grant date, and an additional 6.25% of the RSUs vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.

2. The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on February 11, 2025 and vest in accordance with the following schedule: 25% of the RSUs vested upon the one-year anniversary of the grant date, and an additional 6.25% of the RSUs vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.

3. The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on March 4, 2026 and vest in accordance with the following schedule: 25% of the RSUs vested upon the one-year anniversary of the grant date, and an additional 6.25% of the RSUs vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.

4. The options reported in this row are the remaining outstanding options from a grant of 39,000 options that were granted to the Reporting Person on December 1, 2023 and that have been vesting in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.

5. The options reported in this row were granted to the Reporting Person on February 26, 2024 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.

6. The options reported in this row were granted to the Reporting Person on February 11, 2025 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.

7. The options reported in this row were granted to the Reporting Person on March 4, 2026 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.

	/s/ Yaron Meyer, attorney-in-fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)